Thermo Fisher Scientific Inc. (TMO)
Thermo Fisher Scientific Inc. (TMO) Wolfe 2024 Healthcare Conference (Transcript)
Thermo Fisher Scientific Inc. (NYSE:TMO ) Wolfe 2024 Healthcare Results Conference November 19, 2024 8:00 AM ET Company Participants Marc Casper - Chairman, President and Chief Executive Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody.
Thermo Fisher Scientific: Near The Bottom And Attractively Valued
Thermo Fisher Scientific has strong growth prospects due to easing COVID-19 headwinds, improving Chinese and biotech markets, and favorable funding environments. The company's margins should benefit from volume leverage, cost-saving initiatives, M&A synergies, and favorable price/mix as organic growth improves. TMO's valuation is attractive, trading at a discount to historical averages and peers like Danaher, suggesting potential for P/E multiple re-rating.
Why Thermo Fisher (TMO) International Revenue Trends Deserve Your Attention
Explore how Thermo Fisher's (TMO) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Tradepulse Power Inflow Alert: Thermo Fisher Scientific Inc. Climbs Over 9 Points On Session After Alert
Thermo Fisher Scientific, Inc. today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.
Thermo Fisher Scientific Inc. (TMO) Q3 2024 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q3 2024 Earnings Conference Call October 23, 2024 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President and Chief Executive Officer Stephen Williamson - Senior Vice President and Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Rachel Vatnsdal - JPMorgan Jack Meehan - Nephron Research Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good morning, ladies and gentlemen and welcome to the Thermo Fisher Scientific 2024 Third Quarter Conference Call. My name is Ezra and I will be your coordinator today.
Thermo Fisher (TMO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Thermo Fisher Q3 Earnings Top Estimates, Revenues Miss, Stock Dips
In the third quarter of 2024, TMO continued to advance its growth strategy and trusted partner status with customers.
Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
I am upgrading Thermo Fisher Scientific Inc. to a “Buy” with a fair value of $610 per share due to anticipated recovery in the pharma and biotech industries. Thermo Fisher's high-impact innovations and strategic M&A, including the acquisition of Olink, support a 7%-9% organic revenue growth and mid-teens EPS growth. Q3 results show stabilization in life sciences, with raised full-year adjusted EPS guidance, maintaining revenue guidance of $42.4 to $43.3 billion.
Thermo Fisher Scientific (TMO) Q3 Earnings Top Estimates
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.28 per share, beating the Zacks Consensus Estimate of $5.25 per share. This compares to earnings of $5.69 per share a year ago.
Thermo Fisher raises profit forecast on strong demand for its tools and services
Thermo Fisher Scientific on Wednesday raised the lower end of its annual profit forecast, tweaking it for the third time this year, betting on improved demand for its tools and services used in drug development.
Thermo Fisher (TMO) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Thermo Fisher Scientific (TMO) Expected to Beat Earnings Estimates: Should You Buy?
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
